Publications

Blackstock AW, Benson AB, Kudo M, Jimenez H, Achari PF, et al. 2021. “Safety and Efficacy of amplitudemodulated radiofrequency electromagnetic fields in advanced hepatocellular carcinoma.”
4open, 4, 3

Published online: July 26, 2021
https://www.4open-sciences.org/articles/fopen/pdf/2021/01/fopen210003.pdf

 

J. Camacho, “Hepatocellular carcinoma therapy finds a channel on the radio”
EBioMedicine 

Published online: May 31, 2019
https://www.ebiomedicine.com/article/S2352-3964(19)30368-8/pdf

 

Hugo Jimenez, Minghui Wang, Jacquelyn W. Zimmerman, Michael J. Pennison, Sambad Sharma, Trevor Surratt, Zhi-Xiang Xu, Ivan Brezovich, et al. “Tumour-specific amplitude-modulated radiofrequency electromagneticfields induce differentiation of hepatocellular carcinoma via targetingCav3.2 T-type voltage-gated calcium channels and Ca2+influx”
Publication stage: In Press Corrected Proof
EBioMedicine

Published online: May 31, 2019
https://www.ebiomedicine.com/article/S2352-3964(19)30342-1/pdf

 

Sambad Sharma, Shih-Ying Wu, Hugo Jimenez, Fei Xing, Dongqin Zhu, Yin Liu, Kerui Wu, Abhishek Tyagi, et al. “Ca2+ and CACNA1H mediate targeted suppression of breast cancer brainmetastasis by AM RF EMF”
Publication stage: In Press Corrected Proof
EBioMedicine

Published online: May 22, 2019
https://www.ebiomedicine.com/article/S2352-3964(19)30346-9/pdf

 

“How tumor-specific modulation frequencies were discovered”

THE CANCER LETTER – October 5, 2018
Download the article here

 

Jimenez, H., Blackman, C., Lesser, G., Debinski, W., Chan, M., Sharma, S., Watabe, K., Lo, H.W., Thomas, A., Godwin, D., Blackstock, W., Mudry, A., Posey, J., O’Connor, R., Brezovich, I., Bonin, K., Kim-Shapiro, D., Barbault, A., Pasche. B. (2018). “Use of non-ionizing electromagnetic fields for the treatment of cancer”. Front Biosci (Landmark Ed), 23, 284-297.

PMID: 28930547
https://www.bioscience.org/2018/v23/af/4591/2.htm

 

Capstick M., Gong Y., Pasche B., Kuster N. (2016). “An HF exposure system for mice with improved efficiency”. Bioelectromagnetic, 37, 223-233.

PMID: 27037618
https://onlinelibrary.wiley.com/doi/abs/10.1002/bem.21969

 

Jacquelyn W. Zimmerman , Hugo Jimenez , Michael J. Pennison , Ivan Brezovich , Desiree Morgan , Albert Mudry , Frederico P. Costa , Alexandre Barbault and Boris Pasche. (2013). “Targeted treatment of cancer with radiofrequency electromagnetic fields amplitude-modulated at tumor-specific frequencies”. Chinese Journal of Cancer, 32, 573-581.

PMID 24206915
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3845545/

 

Zimmerman, J., Pennison, M., Brezovich, I., Yi, N., Yang, C.T., Ramaker, R., Absher, D., Myers, R.M., Kuster, N., Costa, F.P., Barbault, A., Pasche, B. (2012). “Cancer cell proliferation is inhibited by specific modulation frequencies”. British Journal of Cancer, 106, 307-313.

PMID: 22134506
https://www.nature.com/articles/bjc2011523

 

Accompanied by the following editorial:
Blackman, C.F. (2012). “Treating cancer with amplitude-modulated electromagnetic fields: a potential paradigm shift, again”? British Journal of Cancer, 106, 241-241.

PMID 22251967
https://www.nature.com/articles/bjc2011576

 

Costa, F.P., Cosme de Oliveira, A., Meirelles Jr, R., Machado, M.C.C., Zanesco, T., Surjan, R., Chammas, M.C., de Souza Rocha, M., Morgan, D., Cantor, A., Ivan Brezovich, Niels Kuster, Barbault, A., Pasche, B. (2011). “Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields”. British Journal of Cancer, 105, 640-648.

PMID: 21829195
https://www.nature.com/articles/bjc2011292

 

Barbault, A., Costa, F.P., Bottger, B., Munden, R.F., Bomholt, F., Kuster, N., Pasche, B. (2009). “Amplitude-modulated electromagnetic fields for the treatment of cancer: Discovery of tumor-specific frequencies and assessment of a novel therapeutic approach”. Journal of Experimental and Clinical Cancer Research, 28, 51.

PMID: 19366446
https://jeccr.biomedcentral.com/articles/10.1186/1756-9966-28-51

 

Pasche, B., Jimenez, H., Zimmerman, J., Barbault, A.
Systemic Treatment of Cancer with Low and Safe Levels of Radiofrequency Electromagnetic Fields Amplitude-Modulated at Tumor-Specific Frequencies.

In: Paul J.Rosch, ed. Bioelectromagnetic and Subtle Energy Medicine. 2nd ed. London, England: CRC Press, 2015:299-303

 

Abou-Alfa, G. K., L. Schwartz, S. Ricci, D. Amadori, A. Santoro, A. Figer, G. J. De, J. Y. Douillard, C. Lathia, B. Schwartz, I. Taylor, M. Moscovici and L. B. Saltz (2006). “Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.” Journal of Clinical Oncology 24(26): 4293-4300.

Barbault, A., F. P. Costa, B. Bottger, R. F. Munden, F. Bomholt, N. Kuster and B. Pasche (2009). “Amplitude-modulated electromagnetic fields for the treatment of cancer: discovery of tumor-specific frequencies and assessment of a novel therapeutic approach.” J Exp Clin Cancer Res 28(1): 51.

Bruix, J., S. Qin, P. Merle, A. Granito, Y.-H. Huang, G. Bodoky, M. Pracht, O. Yokosuka, O. Rosmorduc, V. Breder, R. Gerolami, G. Masi, P. J. Ross, T. Song, J.-P. Bronowicki, I. Ollivier-Hourmand, M. Kudo, A.-L. Cheng, J. M. Llovet, R. S. Finn, M.-A. LeBerre, A. Baumhauer, G. Meinhardt and G. Han (2017). “Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.” The Lancet 389(10064): 56-66.

Costa, F. P., A. C. de Oliveira, R. Meirelles, M. C. C. Machado, T. Zanesco, R. Surjan, M. C. Chammas, M. de Souza Rocha, D. Morgan, A. Cantor, J. Zimmerman, I. Brezovich, N. Kuster, A. Barbault and B. Pasche (2011). “Treatment of advanced hepatocellular carcinoma with very low levels of amplitude-modulated electromagnetic fields.” Br J Cancer 105(5): 640-648.

Eisenhauer, E. A., P. Therasse, J. Bogaerts, L. H. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, L. Rubinstein, L. Shankar, L. Dodd, R. Kaplan, D. Lacombe and J. Verweij (2009). “New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).” European Journal of Cancer 45(2): 228-247.

Lencioni, R. and J. M. Llovet (2010). “Modified RECIST (mRECIST) Assessment for Hepatocellular Carcinoma.” Semin Liver Dis 30(01): 052-060.

Therasse, P., S. G. Arbuck, E. A. Eisenhauer, J. Wanders, R. S. Kaplan, L. Rubinstein, J. Verweij, M. Van Glabbeke, A. T. van Oosterom, M. C. Christian and S. G. Gwyther (2000). “New Guidelines to Evaluate the Response to Treatment in Solid Tumors.” JNCI Journal of the National Cancer Institute 92(3): 205-216.

Zhu, A. X., J. O. Park, B.-Y. Ryoo, C.-J. Yen, R. Poon, D. Pastorelli, J.-F. Blanc, H. C. Chung, A. D. Baron, T. E. F. Pfiffer, T. Okusaka, K. Kubackova, J. Trojan, J. Sastre, I. Chau, S.-C. Chang, P. B. Abada, L. Yang, J. D. Schwartz and M. Kudo (2015). “Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial.” The Lancet Oncology 16(7): 859-870.